ProteoGenix presents abstracts on the company's research regarding proteomic biomarkers associated with critical conditions of pregnancy at 2009 Annual Meeting of the Society of Maternal-Fetal Medicine

January 25, 2009 :: San Diego, CA :: ProteoGenix presented seven abstracts related to the company's research in identifying proteomic biomarkers associated with critical conditions pregnancy at the 2009 Annual Meeting of the Society of Maternal-Fetal Medicine, held in San Diego, CA, January 23 - 27. The ProteoGenix abstracts focused on the companies research with key biological fluids related to pregnancy such as umbilical cord blood, cervical-vaginal fluid and maternal serum. ProteoGenix utilizes sophisticated and proprietary mass spectrometry related technology and techniques to identify proteomic biomarkers that are associated with critical pregnancy-related complications such as intraamniotic infection, early onset neonatal sepsis in premature neonates, recurrent preterm birth and preeclampsia. Of the seven abstracts presented by ProteoGenix, two were work selected by The Society of Maternal- Fetal Medicine for oral presentation by the authors and all have been published in a Supplement to the American Journal of Obstetrics and Gynecology.

ProteoGenix believes this research builds on the company's previous work to create a scientific platform for the discovery, development and commercialization of innovative, primarily noninvasive predictive and diagnostic tests. These products can provide clinicians with improved capability to diagnose and treat these critical conditions associated with pregnancy, many of which have significant clinical and economic consequences.

ProteoGenix is a privately held company with facilities in California and Oregon that is dedicated to the discovery and development of innovative diagnostic testing products for the maternal-fetal health community.